A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar

Autor: Patrick Cobb, Dietger Niederwieser, Stanley Cohen, Caroline Hamm, Gerd Burmester, Neungseon Seo, Sonya G Lehto, Vladimir Hanes

Publikováno v: Immunotherapy. 14:727-740

ABP 798 (RIABNI™) is a biosimilar to rituximab reference product (RP), a monoclonal antibody that targets CD20. Approval of ABP 798 was based on the totality of evidence generated using a stepwise approach which began by showing that it is structur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35b8431751c776ffb9811e9b68fe42f2
https://doi.org/10.2217/imt-2022-0024

PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache?

Autor: Licheng Shi, Bryan D. Moyer, Margarida Martins-Oliveira, Hong Sun, Sonya G. Lehto, Peter J. Goadsby, Simon Akerman, Jan Hoffmann, Dawn Zhu, Weera Supronsinchai, Ruoyuan Yin, Cen Xu, Silke Miller, Judy Wang, Hantao Liu

Publikováno v: Hoffmann, J R, Miller, S, Martins-Oliveira, M, Akerman, S, Supronsinchai, W, Sun, H, Shi, L, Wang, J, Zhu, D, Lehto, S, Liu, H, Yin, R, Moyer, B D, Xu, C & Goadsby, P 2020, ' PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache? ', Pain, vol. 161, no. 7, pp. 1670-1681 . https://doi.org/10.1097/j.pain.0000000000001858
Pain

PAC1 receptor blockade using a monoclonal antibody inhibits nociceptive neuronal activity in the trigeminocervical complex.
Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) may play an important role in primary headaches. Preclini

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e0f35bc013beddca80233ef15c9e0b8
https://doi.org/10.1097/j.pain.0000000000001858

Crystal structures of human glycine receptor α3 bound to a novel class of analgesic potentiators

Autor: Shuyan Yi, Sonya G. Lehto, Stefan I. McDonough, Klaus Michelsen, Erin F. DiMauro, Hao Chen, Maosheng Zhang, Stephen Schneider, Shawn Ayube, Jason A. Luther, Matthew H. Plant, Xin Huang, David J. Matson, Jeffrey R. Simard, Howard Bregman, Jacinthe Gingras, Paul L. Shaffer, Yohannes Teffera

Publikováno v: Nature Structural & Molecular Biology. 24:108-113

Current therapies to treat persistent pain and neuropathic pain are limited by poor efficacy, side effects and risk of addiction. Here, we present a novel class of potent selective, central nervous system (CNS)-penetrant potentiators of glycine recep

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e4d3f9eaf357c8330409b932db69a7e
https://doi.org/10.1038/nsmb.3329

AMG2850, a potent and selective TRPM8 antagonist, is not effective in rat models of inflammatory mechanical hypersensitivity and neuropathic tactile allodynia

Autor: Cheryl L. Stucky, Patrick C. Kerstein, Maosheng Zhang, Kenneth D. Wild, Beth D. Youngblood, Carl Davis, Judy Wang, Weiya Wang, Andy D. Weyer, Sonya G. Lehto, Narender R. Gavva

Publikováno v: Naunyn-Schmiedeberg's Archives of Pharmacology

TRPM8 has been implicated in pain and migraine based on dorsal root- and trigeminal ganglion-enriched expression, upregulation in preclinical models of pain, knockout mouse studies, and human genetics. Here, we evaluated the therapeutic potential in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3200e74bacd3a064fa87df6decbd3609
https://doi.org/10.1007/s00210-015-1090-9

The Discovery and Hit-to-Lead Optimization of Tricyclic Sulfonamides as Potent and Efficacious Potentiators of Glycine Receptors

Autor: Shawn Ayube, Hao Chen, Yohannes Teffera, Jacinthe Gingras, Paul L. Shaffer, Paul Krolikowski, Angel Guzman-Perez, Kristin L. Andrews, Hakan Gunaydin, Richard Thomas Lewis, Klaus Michelsen, Jiali Hu, Liyue Huang, Sonya G. Lehto, Pamela Pegman, Erin F. DiMauro, Howard Bregman, Shuyan Yi, Xin Huang, Maosheng Zhang, Matthew H. Plant, Jeffrey R. Simard

Publikováno v: Journal of medicinal chemistry. 60(3)

Current pain therapeutics suffer from undesirable psychotropic and sedative side effects, as well as abuse potential. Glycine receptors (GlyRs) are inhibitory ligand-gated ion channels expressed in nerves of the spinal dorsal horn, where their activa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0578c8ef3924f9ebf3c9f90bbe82708
https://pubmed.ncbi.nlm.nih.gov/28001399